184 related articles for article (PubMed ID: 31735553)
1. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
2. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
[TBL] [Abstract][Full Text] [Related]
3. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
4. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.
Griffiths PD; Stanton A; McCarrell E; Smith C; Osman M; Harber M; Davenport A; Jones G; Wheeler DC; O'Beirne J; Thorburn D; Patch D; Atkinson CE; Pichon S; Sweny P; Lanzman M; Woodford E; Rothwell E; Old N; Kinyanjui R; Haque T; Atabani S; Luck S; Prideaux S; Milne RS; Emery VC; Burroughs AK
Lancet; 2011 Apr; 377(9773):1256-63. PubMed ID: 21481708
[TBL] [Abstract][Full Text] [Related]
6. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
[TBL] [Abstract][Full Text] [Related]
7. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
8. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
[TBL] [Abstract][Full Text] [Related]
10. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
11. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
12. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
[TBL] [Abstract][Full Text] [Related]
13. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
14. Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
Yamaguchi K; Shimizu H; Takahashi K; Nagatomo T; Nishimura T; Matsumoto M; Koshizuka T; Mori H; Inoue N; Torikai M
Vaccine; 2023 Jul; 41(31):4497-4507. PubMed ID: 37321896
[TBL] [Abstract][Full Text] [Related]
15. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
16. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
18. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
19. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of rhesus cytomegalovirus IL-10 reduces horizontal transmission and alters long-term immunity.
Deere JD; Chang WLW; Villalobos A; Schmidt KA; Deshpande A; Castillo LD; Fike J; Walter MR; Barry PA; Hartigan-O'Connor DJ
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13036-13041. PubMed ID: 31189602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
